RHY Executes SE Asian Genetype Distribution Agreement
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Rhythm Biosciences Limited has executed a Supply and Distribution Agreement with Digistain Limited for its geneType™ genetic test portfolio in Southeast Asia, starting with the Philippines as the initial market. This marks Rhythm's first formal entry into the Southeast Asian market, aiming to leverage Digistain's established distribution networks. The agreement is expected to generate revenue on a per-test basis as samples are processed, although specific revenue guidance cannot be provided at this early stage.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- Exercise of RHYO Options underwritten for $4.5m to $6.0m
- Trading Halt
- Half-Year Financial Report and Appendix 4D
- Rhythm Bio enters ColoSTAT agreement with 4Cyte Pathology
- ColoSTAT commercial deployment - First physician enrolled
Later from Rhythm Biosciences
- NATA Accredits ColoSTAT Clinical Testing Service
- First ColoSTAT Clinical Test Sale
- Response to ASX Query Letter
- Quarterly Activities Report and Appendix 4C
- Bioshares 2026 Presentation
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences